Amgen Provides Regulatory Update on Status of Lumakras (sotorasib)

THOUSAND OAKS, Calif., Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company ' s supplemental New Drug Application seeking full approval of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news